Abstract:Neurological disorders are the second cause of death and the leading cause of disability worldwide. Unfortunately, no cure exists for these disorders, but the actual therapies are only able to ameliorate people's quality of life. Thus, there is an urgent need to test potential therapeutic approaches. Brain organoids are a possible valuable tool in the study of the brain, due to their ability to reproduce different brain regions and maturation stages; they can be used also as a tool for disease modelling and target identification of neurological disorders. Recently, brain organoids have been used in drug-screening processes, even if there are several limitations to overcome. This review focuses on the description of brain organoid development and drug-screening processes, discussing the advantages, challenges, and limitations of the use of organoids in modeling neurological diseases. We also highlighted the potential of testing novel therapeutic approaches. Finally, we examine the challenges and future directions to improve the drug-screening process.

What problem does this paper attempt to address?

The paper mainly discusses the application of brain organoids in drug testing and how they may change the game rules in this field. Neurological disorders are the second leading cause of death and the leading cause of disability worldwide, but effective treatments are currently lacking. Brain organoids, three-dimensional cell culture models derived from human stem cells, can mimic different regions and stages of the brain, making them useful for disease modeling and target identification in neurological disorders. The article points out that although brain organoids have been used in the drug screening process, there are still limitations such as core necrosis due to lack of vascularization. The paper reviews the development of brain organoids, the process of drug screening, discusses the advantages of using organoid modeling for neurological diseases (such as reflecting disease heterogeneity, simulating neural networks, etc.), challenges (such as tissue heterogeneity, scalability, and maturity issues), and limitations, and proposes future improvements in drug screening. In addition, the paper briefly introduces the general background of neurological disorders, including their diversity, risk factors, and diagnostic challenges. The study also covers the use of brain organoids to study various diseases such as Alzheimer's disease, Parkinson's disease, brain tumors, etc. Finally, the paper emphasizes the potential of brain organoids in drug discovery and screening, while also pointing out the barriers that need to be overcome when applying organoid technology to preclinical and clinical trials.

Brain Organoids: A Game-Changer for Drug Testing